Hormonal treatments for endometriosis: The endocrine background

1.

Chapron C, Marcellin L, Borghese B, Santulli P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019. https://doi.org/10.1038/s41574-019-0245-z.CrossRefPubMed

2.

Buck Louis GM, Hediger ML, Peterson CM, et al. Incidence of endometriosis by study population and diagnostic method: The ENDO study. Fertil Steril. 2011. https://doi.org/10.1016/j.fertnstert.2011.05.087.CrossRefPubMedPubMedCentral

3.

Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis Nat Rev Dis Prim. 2018;4(1):9. https://doi.org/10.1038/s41572-018-0008-5.CrossRefPubMed

4.

Reis FM, Petraglia F, Taylor RN. Endometriosis: Hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013;19(4):406–18. https://doi.org/10.1093/humupd/dmt010.CrossRefPubMedPubMedCentral

5.

Reis FM, Coutinho LM, Vannuccini S, Batteux F, Chapron C, Petraglia F. Progesterone receptor ligands for the treatment of endometriosis: The mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020. https://doi.org/10.1093/humupd/dmaa009.CrossRefPubMedPubMedCentral

6.

Patel BG, Lenk EE, Lebovic DI, Shu Y, Yu J, Taylor RN. Pathogenesis of endometriosis: Interaction between Endocrine and inflammatory pathways. Best Pract Res Clin Obstet Gynaecol. 2018. https://doi.org/10.1016/j.bpobgyn.2018.01.006.CrossRefPubMed

7.

Han SJ, O’Malley BW. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum Reprod Update. 2014;20(4):467–84. https://doi.org/10.1093/humupd/dmu002.CrossRefPubMedPubMedCentral

8.

Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98(3):511–9. https://doi.org/10.1016/j.fertnstert.2012.06.029.CrossRefPubMed

9.

Benagiano G, Brosens I, Habiba M. Structural and molecular features of the endomyometrium in endometriosis and adenomyosis. Hum Reprod Update. 2014;20(3):386–402. https://doi.org/10.1093/humupd/dmt052.CrossRefPubMed

10.

Leyendecker G, Bilgicyildirim A, Inacker M, et al. Adenomyosis and endometriosis. Re-visiting their association and further insights into the mechanisms of auto-traumatisation. An MRI study. Arch Gynecol Obstet. 2015;291(4):917–32. https://doi.org/10.1007/s00404-014-3437-8.

11.

Filippi I, Carrarelli P, Luisi S, et al. Different Expression of Hypoxic and Angiogenic Factors in Human Endometriotic Lesions. Reprod Sci. 2016. https://doi.org/10.1177/1933719115607978.CrossRefPubMed

12.

Gori M, Luddi A, Belmonte G, et al. Expression of microtubule associated protein 2 and synaptophysin in endometrium: high levels in deep infiltrating endometriosis lesions. Fertil Steril. 2016;105(2):435–43. https://doi.org/10.1016/j.fertnstert.2015.10.024.CrossRefPubMed

13.

Guo SW. Fibrogenesis resulting from cyclic bleeding: The Holy Grail of the natural history of ectopic endometrium. Hum Reprod. 2018. https://doi.org/10.1093/humrep/dey015.CrossRefPubMedPubMedCentral

14.

Chamié LP, Ribeiro DMFR, Tiferes DA, De Macedo Neto AC, Serafini PC. Atypical sites of deeply infiltrative endometriosis: Clinical characteristics and imaging findings. Radiographics. 2018. https://doi.org/10.1148/rg.2018170093.CrossRefPubMed

15.

Vannuccini S, Tosti C, Carmona F, et al. Pathogenesis of adenomyosis: An update on molecular mechanisms. Reprod Biomed Online. 2017. https://doi.org/10.1016/j.rbmo.2017.06.016.CrossRefPubMed

16.

Vannuccini S, Petraglia F. Recent advances in understanding and managing adenomyosis. F1000Research. 2019;8. https://doi.org/10.12688/f1000research.17242.1.

17.

Agarwal SK, Chapron C, Giudice LC, et al. Clinical diagnosis of endometriosis: a call to action. Am J Obstet Gynecol. 2019. https://doi.org/10.1016/j.ajog.2018.12.039.CrossRefPubMed

18.

De Graaff AA, D’hooghe TM, Dunselman GAJ, et al. The significant effect of endometriosis on physical, mental and social wellbeing: Results from an international cross-sectional survey. Hum Reprod. 2013;28(10):2677–85. https://doi.org/10.1093/humrep/det284.

19.

Marinho MCP, Magalhaes TF, Fernandes LFC, Augusto KL, Brilhante AVM, Bezerra LRPS. Quality of Life in Women with Endometriosis: An Integrative Review. J Women’s Heal. 2018. https://doi.org/10.1089/jwh.2017.6397.CrossRef

20.

Treatment of pelvic pain associated with endometriosis. A committee opinion. Fertil Steril. 2014. https://doi.org/10.1016/j.fertnstert.2014.02.012.CrossRef

21.

Clemenza S, Sorbi F, Noci I, et al. From pathogenesis to clinical practice: Emerging medical treatments for endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018. https://doi.org/10.1016/j.bpobgyn.2018.01.021.CrossRefPubMed

22.

Ceccaroni M, Bounous VE, Clarizia R, Mautone D, Mabrouk M. Recurrent endometriosis: a battle against an unknown enemy. Eur J Contracept Reprod Heal Care. 2019. https://doi.org/10.1080/13625187.2019.1662391.CrossRef

23.

Ianieri MM, Mautone D, Ceccaroni M. Recurrence in Deep Infiltrating Endometriosis: A Systematic Review of the Literature. J Minim Invasive Gynecol. 2018. https://doi.org/10.1016/j.jmig.2017.12.025.CrossRefPubMed

24.

Ferrero S, Barra F, Leone Roberti Maggiore U. Current and Emerging Therapeutics for the Management of Endometriosis. Drugs. 2018;78(10):995–1012. https://doi.org/10.1007/s40265-018-0928-0.

25.

Capezzuoli T, Vannuccini S, Mautone D, et al. Long-term hormonal treatment reduces repetitive surgery for endometriosis recurrence. Reprod Biomed Online. 2020. https://doi.org/10.1016/j.rbmo.2020.09.018.CrossRefPubMed

26.

Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opin Drug Metab Toxicol. 2018;14(4):399–415. https://doi.org/10.1080/17425255.2018.1461840.CrossRefPubMed

27.

Méar L, Herr M, Fauconnier A, Pineau C, Vialard F. Polymorphisms and endometriosis: A systematic review and meta-analyses. Hum Reprod Update. 2020. https://doi.org/10.1093/humupd/dmz034.CrossRefPubMed

28.

André GM, Martins Trevisan C, Pedruzzi IN, et al. The impact of FSHR gene polymorphisms Ala307Thr and Asn680Ser in the endometriosis development. DNA Cell Biol. 2018. https://doi.org/10.1089/dna.2017.4093.CrossRefPubMed

29.

Wang HS, Cheng BH, Wu HM, et al. A mutant single nucleotide polymorphism of follicle-stimulating hormone receptor is associated with a lower risk of endometriosis. Fertil Steril. 2011. https://doi.org/10.1016/j.fertnstert.2010.07.1092.CrossRefPubMedPubMedCentral

30.

Kerimoglu OS, Yılmaz SA, Pekin A, et al. Follicle-stimulating hormone receptor gene polymorphisms in women with endometriosis. Arch Gynecol Obstet. 2015. https://doi.org/10.1007/s00404-014-3562-4.CrossRefPubMed

31.

Bosco L, Ruvolo G, Luparello C, et al. Gene Expression and Apoptosis Levels in Cumulus Cells of Patients with Polymorphisms of FSHR and LHB Undergoing in Vitro Fertilization Program. Cell Physiol Biochem. 2017. https://doi.org/10.1159/000484392.CrossRefPubMed

32.

Schmitz CR, de Souza CAB, Genro VK, Matte U, de Conto E, Cunha-Filho JS. LH (Trp8Arg/Ile15Thr), LHR (insLQ) and FSHR (Asn680Ser) polymorphisms genotypic prevalence in women with endometriosis and infertility. J Assist Reprod Genet. 2015. https://doi.org/10.1007/s10815-015-0477-3.CrossRefPubMedPubMedCentral

33.

Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis. Endocr Rev. 2019. https://doi.org/10.1210/er.2018-00242.CrossRefPubMedPubMedCentral

34.

Noble LS, Simpson ER, Johns A, Bulun SE. Aromatase expression in endometriosis. J Clin Endocrinol Metab. 1996. https://doi.org/10.1210/jcem.81.1.8550748.CrossRefPubMed

35.

Zeitoun K, Takayama K, Sasano H, et al. Deficient 17β-hydroxysteroid dehydrogenase type 2 expression in endometriosis: Failure to metabolize 17β-estradiol. J Clin Endocrinol Metab. 1998. https://doi.org/10.1210/jcem.83.12.5301.CrossRefPubMed

36.

Bulun SE, Cheng YH, Yin P, et al. Progesterone resistance in endometriosis: Link to failure to metabolize estradiol. Mol Cell Endocrinol. 2006. https://doi.org/10.1016/j.mce.2005.11.041.

37.

Bulun SE, Utsunomiya H, Lin Z, et al. Steroidogenic factor-1 and endometriosis. Mol Cell Endocrinol. 2009. https://doi.org/10.1016/j.mce.2008.12.012.CrossRefPubMed

38.

Attar E, Tokunaga H, Imir G, et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. J Clin Endocrinol Metab. 2009. https://doi.org/10.1210/jc.2008-1180.CrossRefPubMed

39.

Yilmaz BD, Bulun SE. Endometriosis and nuclear receptors. Hum Reprod Update. 2019. https://doi.org/10.1093/humupd/dmz005.CrossRefPubMedPubMedCentral

40.

Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-β in endometriosis. Semin Reprod Med. 2012. https://doi.org/10.1055/s-0031-1299596.CrossRefPubMedPubMedCentral

41.

Xue Q, Lin Z, Cheng YH, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biol Reprod. 2007. https://doi.org/10.1095/biolreprod.107.061804.CrossRefPubMed

42.

Patel B, Elguero S, Thakore S, Dahoud W, Bedaiwy M, Mesiano S. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015;21(2):155–73. https://doi.org/10.1093/humupd/dmu056.CrossRefPubMed

43.

Juhasz-Böss I, Fischer C, Lattrich C, et al. Endometrial expression of estrogen receptor β and its splice variants in patients with and without endometriosis. Arch Gynecol Obstet. 2011. https://doi.org/10.1007/s00404-010-1768-7.CrossRefPubMed

44.

Kumagami A, Ito A, Yoshida-Komiya H, Fujimori K, Sato A. Expression patterns of the steroid receptor coactivator family in human ovarian endometriosis. J Obstet Gynaecol Res. 2011. https://doi.org/10.1111/j.1447-0756.2010.01509.x.CrossRefPubMed

45.

Han SJ, Hawkins SM, Begum K, et al. A new isoform of steroid receptor coactivator-1 is crucial for pathogenic progression of endometriosis. Nat Med. 2012. https://doi.org/10.1038/nm.2826.CrossRefPubMedPubMedCentral

46.

Han SJ, Jung SY, Wu SP, et al. Estrogen Receptor β Modulates Apoptosis Complexes and the Inflammasome to Drive the Pathogenesis of Endometriosis. Cell. 2015;163(4):960–74. https://doi.org/10.1016/j.cell.2015.10.034.CrossRefPubMedPubMedCentral

47.

Bulun SE, Monsavais D, Pavone ME, et al. Role of estrogen receptor-beta in endometriosis. Semin Reprod Med. 2012;30(1):39–45. https://doi.org/10.1055/s-0031-1299596.CrossRefPubMedPubMedCentral

48.

Reis FM, Petraglia F, Taylor RN. Endometriosis: Hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013. https://doi.org/10.1093/humupd/dmt010.CrossRefPubMedPubMedCentral

49.

Dmowski WP, Ding J, Shen J, Rana N, Fernandez BB, Braun DP. Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. Hum Reprod. 2001. https://doi.org/10.1093/humrep/16.9.1802.CrossRefPubMed

50.

Han SJ, Jung SY, Wu SP, et al. Estrogen Receptor β Modulates Apoptosis Complexes and the Inflammasome to Drive the Pathogenesis of Endometriosis. Cell. 2015. https://doi.org/10.1016/j.cell.2015.10.034.CrossRefPubMedPubMedCentral

51.

Greaves E, Temp J, Esnal-Zufiurre A, Mechsner S, Horne AW, Saunders PTK. Estradiol Is a Critical Mediator of Macrophage-Nerve Cross Talk in Peritoneal Endometriosis. Am J Pathol. 2015. https://doi.org/10.1016/j.ajpath.2015.04.012.CrossRefPubMedPubMedCentral

52.

Montagna P, Capellino S, Villaggio B, et al. Peritoneal fluid macrophages in endometriosis: correlation between the expression of estrogen receptors and inflammation. Fertil Steril. 2008. https://doi.org/10.1016/j.fertnstert.2006.11.200.CrossRefPubMed

53.

Patel BG, Rudnicki M, Yu J, Shu Y, Taylor RN. Progesterone resistance in endometriosis: origins, consequences and interventions. Acta Obstet Gynecol Scand. 2017;96(6):623–32. https://doi.org/10.1111/aogs.13156.CrossRefPubMed

54.

Burney RO, Talbi S, Hamilton AE, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007. https://doi.org/10.1210/en.2006-1692.CrossRefPubMed

55.

Kao LC, Germeyer A, Tulac S, et al. Expression profiling of endometrium from women with endometriosis reveals candidate genes for disease. Based implantation failure and infertility. Endocrinology. 2003. https://doi.org/10.1210/en.2003-0043.CrossRefPubMed

56.

Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012. https://doi.org/10.1016/j.fertnstert.2012.06.029.CrossRefPubMedPubMedCentral

57.

Attia GR, Zeitoun K, Edwards D, Johns A, Carr BR, Bulun SE. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab. 2000. https://doi.org/10.1210/jc.85.8.2897.CrossRefPubMed

58.

Near AM, Wu AH, Templeman C, et al. Progesterone receptor gene polymorphisms and risk of endometriosis: Results from an international collaborative effort. Fertil Steril. 2011;95(1):40–5. https://doi.org/10.1016/j.fertnstert.2010.06.059.CrossRefPubMed

59.

Wieser F, Schneeberger C, Tong D, Tempfer C, Huber JC, Wenzl R. PROGINS receptor gene polymorphism is associated with endometriosis. Fertil Steril. 2002;77(2):309–12. https://doi.org/10.1016/S0015-0282(01)02984-3.CrossRefPubMed

60.

Pabalan N, Salvador A, Jarjanazi H, Christofolini DM, Barbosa CP, Bianco B. Association of the progesterone receptor gene polymorphism (PROGINS) with endometriosis: a meta-analysis. Arch Gynecol Obstet. 2014. https://doi.org/10.1007/s00404-014-3308-3.CrossRefPubMed

61.

Barragan F, Irwin JC, Balayan S, et al. Human Endometrial Fibroblasts Derived from Mesenchymal Progenitors Inherit Progesterone Resistance and Acquire an Inflammatory Phenotype in the Endometrial Niche in Endometriosis. Biol Reprod. 2016. https://doi.org/10.1095/biolreprod.115.136010.CrossRefPubMedPubMedCentral

62.

Florio P, Luisi S, Viganò P, et al. Healthy women and patients with endometriosis show high concentrations of inhibin A, inhibin B, and activin A in peritoneal fluid throughout the menstrual cycle. Hum Reprod. 1998. https://doi.org/10.1093/humrep/13.9.2606.CrossRefPubMed

63.

Reis FM, Di Blasio AM, Florio P, Ambrosini G, Di Loreto C, Petraglia F. Evidence for local production of inhibin A and activin A in patients with ovarian endometriosis. Fertil Steril. 2001. https://doi.org/10.1016/S0015-0282(00)01720-9.CrossRefPubMed

64.

Mabuchi Y, Yamamoto M, Minami S, Umesaki N. Immunohistochemical localization of inhibin and activin subunits, activin receptors and Smads in ovarian endometriosis. Int J Mol Med. 2010. https://doi.org/10.3892/ijmm_00000308.CrossRefPubMed

65.

Rocha ALL, Carrarelli P, Novembri R, et al. Activin A stimulates interleukin 8 and vascular endothelial growth factor release from cultured human endometrial stromal cells: possible implications for the pathogenesis of endometriosis. Reprod Sci. 2012;19(8):832–8. https://doi.org/10.1177/1933719111434542.CrossRefPubMed

66.

Akiyama I, Yoshino O, Osuga Y, et al. Follistatin is induced by IL-1β and TNF-α in stromal cells from endometrioma. Reprod Sci. 2013. https://doi.org/10.1177/1933719112463253.CrossRefPubMed

67.

Rocha ALL, Carrarelli P, Novembri R, et al. Altered expression of activin, cripto, and follistatin in the endometrium of women with endometrioma. Fertil Steril. 2011. https://doi.org/10.1016/j.fertnstert.2011.03.048.CrossRefPubMed

68.

Cruz C Dela, Del Puerto HL, Rocha ALL, et al. Expression of nodal, cripto, SMAD3, phosphorylated SMAD3, and SMAD4 in the proliferative endometrium of women with endometriosis. Reprod Sci. 2015. https://doi.org/10.1177/1933719114549855.

69.

Reis FM, Luisi S, Abro MS, et al. Diagnostic value of serum activin A and follistatin levels in women with peritoneal, ovarian and deep infiltrating endometriosis. Hum Reprod. 2012. https://doi.org/10.1093/humrep/des055.CrossRefPubMed

70.

Lemos NA, Arbo E, Scalco R, Weiler E, Rosa V, Cunha-Filho JS. Decreased anti-Müllerian hormone and altered ovarian follicular cohort in infertile patients with mild/minimal endometriosis. Fertil Steril. 2008;89(5):1064–8. https://doi.org/10.1016/j.fertnstert.2007.04.048.CrossRefPubMed

71.

Pacchiarotti A, Frati P, Milazzo GN, Catalano A, Gentile V, Moscarini M. Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis. Eur J Obstet Gynecol Reprod Biol. 2014;172(1):62–4. https://doi.org/10.1016/j.ejogrb.2013.10.003.CrossRefPubMed

72.

Streuli I, De Ziegler D, Gayet V, et al. In women with endometriosis anti-Müllerian hormone levels are decreased only in those with previous endometrioma surgery. Hum Reprod. 2012;27(11):3294–303. https://doi.org/10.1093/humrep/des274.CrossRefPubMed

73.

Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2012. https://doi.org/10.1210/jc.2012-1558.CrossRefPubMed

74.

Somigliana E, Berlanda N, Benaglia L, Viganò P, Vercellini P, Fedele L. Surgical excision of endometriomas and ovarian reserve: a systematic review on serum antimüllerian hormone level modifications. Fertil Steril. 2012;98(6):1531–8. https://doi.org/10.1016/j.fertnstert.2012.08.009.CrossRefPubMed

75.

Romanski PA, Brady PC, Farland LV, Thomas AM, Hornstein MD. The effect of endometriosis on the antimüllerian hormone level in the infertile population. J Assist Reprod Genet. 2019;36(6):1179–84. https://doi.org/10.1007/s10815-019-01450-9.CrossRefPubMedPubMedCentral

76.

Hwu YM, Wu FS, Li SH, Sun FJ, Lin MH, Lee RK. The impact of endometrioma and laparoscopic cystectomy on serum anti-Müllerian hormone levels. Reprod Biol Endocrinol. 2011;9(1):80. https://doi.org/10.1186/1477-7827-9-80.CrossRefPubMedPubMedCentral

77.

Kasapoglu I, Ata B, Uyaniklar O, et al. Endometrioma-related reduction in ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018;110(1):122–7. https://doi.org/10.1016/j.fertnstert.2018.03.015.CrossRefPubMed

78.

Maneschi F, Marasá L, Incandela S, Mazzarese M, Zupi E. Ovarian cortex surrounding benign neoplasms: a histologic study. Am J Obstet Gynecol. 1993;169(2 Pt 1):388–93. https://doi.org/10.1016/0002-9378(93)90093-x.CrossRefPubMed

79.

The Effect of Surgery for Endometriomas on Fertility: Scientific Impact Paper No. 55. BJOG. 2018;125(6):e19-28. https://doi.org/10.1111/1471-0528.14834.

80.

Amer SAK. The impact of endometrioma and its surgical treatment on ovarian reserve and reproductive performance. Reprod Surg Assist Concept. 2015:43–57. https://doi.org/10.1007/978-1-4471-4953-8_5.

81.

Kitajima M, Matsumoto K, Murakami N, et al. AMH Concentrations in Peritoneal Fluids of Women With and Without Endometriosis. Front Surg. 2020;7(November):1–8. https://doi.org/10.3389/fsurg.2020.600202.CrossRef

82.

Wang J, Dicken C, Lustbader JW, Tortoriello DV. Evidence for a Müllerian-inhibiting substance autocrine/paracrine system in adult human endometrium. Fertil Steril. 2009;91(4):1195–203. https://doi.org/10.1016/j.fertnstert.2008.01.028.CrossRefPubMed

83.

Namkung J, Song JY, Jo HH, et al. Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis. J Clin Endocrinol Metab. 2012;97(9):3224–30. https://doi.org/10.1210/jc.2012-1538.CrossRefPubMedPubMedCentral

84.

Signorile PG, Petraglia F, Baldi A. Anti-mullerian hormone is expressed by endometriosis tissues and induces cell cycle arrest and apoptosis in endometriosis cells. J Exp Clin Cancer Res. 2014;33(1):46. https://doi.org/10.1186/1756-9966-33-46.CrossRefPubMedPubMedCentral

85.

Galhardo A, Moura-Ramos M, Cunha M, Pinto-Gouveia J. The infertility trap: How defeat and entrapment affect depressive symptoms. Hum Reprod. 2016. https://doi.org/10.1093/humrep/dev311.CrossRefPubMed

86.

Siedentopf F, Tariverdian N, Rücke M, Kentenich H, Arck PC. Immune status, psychosocial distress and reduced quality of life in infertile patients with endometriosis. Am J Reprod Immunol. 2008. https://doi.org/10.1111/j.1600-0897.2008.00644.x.CrossRefPubMed

87.

Soliman AM, Coyne KS, Gries KS, Castelli-Haley J, Snabes MC, Surrey ES. The effect of endometriosis symptoms on absenteeism and presenteeism in the workplace and at home. J Manag Care Spec Pharm. 2017. https://doi.org/10.18553/jmcp.2017.23.7.745.CrossRefPubMed

88.

Luisi S, Pizzo A, Pinzauti S, et al. Neuroendocrine and stress-related aspects of endometriosis. Neuroendocrinol Lett. 2015. PMID: 25789593.

89.

Harrison V, Rowan K, Mathias J. Stress reactivity and family relationships in the development and treatment of endometriosis. Fertil Steril. 2005. https://doi.org/10.1016/j.fertnstert.2004.10.033.CrossRefPubMed

90.

Staal AHJ, Van Der Zanden M, Nap AW. Diagnostic Delay of Endometriosis in the Netherlands. Gynecol Obstet Invest. 2016;81(4):321–4. https://doi.org/10.1159/000441911.CrossRefPubMed

91.

Soliman AM, Fuldeore M, Snabes MC. Factors Associated with Time to Endometriosis Diagnosis in the United States. J Women’s Heal. 2017. https://doi.org/10.1089/jwh.2016.6003.CrossRef

92.

Lazzeri L, Vannuccini S, Orlandini C, et al. Surgical treatment affects perceived stress differently in women with endometriosis: Correlation with severity of pain. Fertil Steril. 2015. https://doi.org/10.1016/j.fertnstert.2014.10.036.CrossRefPubMed

93.

Lazzeri L, Orlandini C, Vannuccini S, Pinzauti S, Tosti C, Zupi E, Nappi RE, Petraglia F. Endometriosis and Perceived Stress : Impact of Surgical and Medical Treatment. Gynecol Obstet Invest. 2015;10:1–5. https://doi.org/10.1159/000368776.CrossRef

94.

Facchin F, Barbara G, Saita E, et al. Impact of endometriosis on quality of life and mental health: Pelvic pain makes the difference. J Psychosom Obstet Gynecol. 2015. https://doi.org/10.3109/0167482X.2015.1074173.CrossRef

95.

Márki G, Bokor A, Rigó J, Rigó A. Physical pain and emotion regulation as the main predictive factors of health-related quality of life in women living with endometriosis. Hum Reprod. 2017. https://doi.org/10.1093/humrep/dex091.CrossRefPubMed

96.

Facchin F, Barbara G, Dridi D, et al. Mental health in women with endometriosis: Searching for predictors of psychological distress. Hum Reprod. 2017. https://doi.org/10.1093/humrep/dex249.CrossRefPubMed

97.

Coxon L, Horne AW, Vincent K. Pathophysiology of endometriosis-associated pain: A review of pelvic and central nervous system mechanisms. Best Pract Res Clin Obstet Gynaecol. 2018. https://doi.org/10.1016/j.bpobgyn.2018.01.014.CrossRefPubMed

98.

Frodl T, O’Keane V. How does the brain deal with cumulative stress? A review with focus on developmental stress, HPA axis function and hippocampal structure in humans. Neurobiol Dis. 2013. https://doi.org/10.1016/j.nbd.2012.03.012.CrossRefPubMed

99.

Fries E, Hesse J, Hellhammer J, Hellhammer DH. A new view on hypocortisolism. Psychoneuroendocrinology. 2005. https://doi.org/10.1016/j.psyneuen.2005.04.006.CrossRefPubMed

100.

Blackburn-Munro G, Blackburn-Munro R. Pain in the brain: Are hormones to blame? Trends Endocrinol Metab. 2003. https://doi.org/10.1016/S1043-2760(02)00004-8.CrossRefPubMed

101.

Ortiz R, Gemmill JAL, Sinaii N, et al. Hypothalamic-Pituitary-Adrenal Axis Responses in Women with Endometriosis-Related Chronic Pelvic Pain. Reprod Sci. 2020. https://doi.org/10.1007/s43032-020-00201-x.CrossRefPubMed

102.

Petrelluzzi KFS, Garcia MC, Petta CA, Grassi-Kassisse DM, Spadari-Bratfisch RC. Salivary cortisol concentrations, stress and quality of life in women with endometriosis and chronic pelvic pain. Stress. 2008. https://doi.org/10.1080/10253890701840610.CrossRefPubMed

103.

Quiñones M, Urrutia R, Torres-Reverón A, Vincent K, Flores I. Anxiety, coping skills and hypothalamus-pituitary-adrenal (HPA) axis in patients with endometriosis. J Reprod Biol Heal. 2015. https://doi.org/10.7243/2054-0841-3-2.CrossRef

104.

van Aken M, Oosterman J, van Rijn T, et al. Hair cortisol and the relationship with chronic pain and quality of life in endometriosis patients. Psychoneuroendocrinology. 2018. https://doi.org/10.1016/j.psyneuen.2018.01.001.CrossRefPubMed

105.

Lima AP, Moura MD, Rosa e Silva AAM. Prolactin and cortisol levels in women with endometriosis. Brazilian J Med Biol Res. 2006. https://doi.org/10.1590/S0100-879X2006000800015.

106.

Friggi Sebe Petrelluzzi K, Garcia MC, Petta CA, et al. Physical therapy and psychological intervention normalize cortisol levels and improve vitality in women with endometriosis. J Psychosom Obstet Gynecol. 2012. https://doi.org/10.3109/0167482X.2012.729625.

107.

Petraglia F, Imperatore A, Challis JRG. Neuroendocrine mechanisms in pregnancy and parturition. Endocr Rev. 2010;31(6):783–816. https://doi.org/10.1210/er.2009-0019.CrossRefPubMed

108.

Novembri R, Borges LE, Carrarelli P, et al. Impaired CRH and urocortin expression and function in eutopic endometrium of women with endometriosis. J Clin Endocrinol Metab. 2011;96(4):1145–50. https://doi.org/10.1210/jc.2010-2263.CrossRefPubMed

109.

Carrarelli P, Luddi A, Funghi L, et al. Urocortin and corticotrophin-releasing hormone receptor type 2 mRNA are highly expressed in deep infiltrating endometriotic lesions. Reprod Biomed Online. 2016;33(4):476–83. https://doi.org/10.1016/j.rbmo.2016.07.009.CrossRefPubMed

110.

Novembri R, Carrarelli P, Toti P, et al. Urocortin 2 and urocortin 3 in endometriosis: evidence for a possible role in inflammatory response. Mol Hum Reprod. 2011;17(9):587–93. https://doi.org/10.1093/molehr/gar020.CrossRefPubMed

111.

Florio P, Reis F, Torres P, et al. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstet Gynecol. 2007;110(3):594–600. https://doi.org/10.1097/01.AOG.0000278572.86019.ae.CrossRefPubMed

112.

Maia LM, Rocha AL, Del Puerto HL, Petraglia F, Reis FM. Plasma urocortin-1 as a preoperative marker of endometriosis in symptomatic women. Gynecol Endocrinol. 2018. https://doi.org/10.1080/09513590.2017.1380188.CrossRefPubMed

113.

Sinaii N, Cleary SD, Ballweg ML, Nieman LK, Stratton P. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod. 2002;17(10):2715–24. https://doi.org/10.1093/humrep/17.10.2715.CrossRefPubMed

114.

Poppe K, Velkeniers B, Glinoer D. The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab. 2008;4(7):394–405. https://doi.org/10.1038/ncpendmet0846.CrossRefPubMed

115.

Yuk JS, Park EJ, Seo YS, Kim HJ, Kwon SY, Park WI. Graves disease is associated with endometriosis: A 3-year population-based cross-sectional study. Med (United States). 2016;95(10):1–5. https://doi.org/10.1097/MD.0000000000002975.CrossRef

116.

Aghajanova L, Giudice LC. Molecular evidence for differences in endometrium in severe versus mild endometriosis. Reprod Sci. 2011;18(3):229–51. https://doi.org/10.1177/1933719110386241.CrossRefPubMedPubMedCentral

117.

Peyneau M, Kavian N, Chouzenoux S, et al. Role of thyroid dysimmunity and thyroid hormones in endometriosis. Proc Natl Acad Sci U S A. 2019;116(24):11894–9. https://doi.org/10.1073/pnas.1820469116.CrossRefPubMedPubMedCentral

118.

Mousa SA, O’Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ. The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol. 2005;46(3):356–60. https://doi.org/10.1097/01.fjc.0000175438.94906.a0.CrossRefPubMed

119.

Stavreus EA. Paracrine interactions of thyroid hormones and thyroid stimulation hormone in the female reproductive tract have an impact on female fertility. Front Endocrinol (Lausanne). 2012;3:50. https://doi.org/10.3389/fendo.2012.00050.CrossRef

120.

DiVasta AD, Vitonis AF, Laufer MR, Missmer SA. Spectrum of symptoms in women diagnosed with endometriosis during adolescence vs adulthood. Am J Obstet Gynecol. 2018. https://doi.org/10.1016/j.ajog.2017.12.007.CrossRefPubMed

121.

Fauconnier A, Chapron C. Endometriosis and pelvic pain: Epidemiological evidence of the relationship and implications. Hum Reprod Update. 2005. https://doi.org/10.1093/humupd/dmi029.CrossRefPubMed

122.

Schliep KC, Mumford SL, Peterson CM, et al. Pain typology and incident endometriosis. Hum Reprod. 2015. https://doi.org/10.1093/humrep/dev147.CrossRefPubMedPubMedCentral

123.

Ballard K, Lane H, Hudelist G, Banerjee S, Wright J. Can specific pain symptoms help in the diagnosis of endometriosis? A cohort study of women with chronic pelvic pain. Fertil Steril. 2010. https://doi.org/10.1016/j.fertnstert.2009.01.164.CrossRefPubMed

124.

Chung MK, Chung RP, Gordon D. Interstitial cystitis and endometriosis in patients with chronic pelvic pain: The “Evil Twins” syndrome. JSLS. 2005.

125.

Redwine DB. Diaphragmatic endometriosis: diagnosis, surgical management, and long-term results of treatment. Fertil Steril. 2002. https://doi.org/10.1016/S0015-0282(01)02998-3.CrossRefPubMed

126.

Fedele L, Berlanda N, Corsi C, Gazzano G, Morini M, Vercellini P. Ileocecal endometriosis: Clinical and pathogenetic implications of an underdiagnosed condition. Fertil Steril. 2014. https://doi.org/10.1016/j.fertnstert.2013.11.126.CrossRefPubMed

127.

Coratti F, Vannuccini S, Foppa C, et al. Emergency surgery for appendectomy and incidental diagnosis of superficial peritoneal endometriosis in fertile age women. Reprod Biomed Online. 2020. https://doi.org/10.1016/j.rbmo.2020.06.008.CrossRefPubMed

128.

Morotti M, Vincent K, Becker CM. Mechanisms of pain in endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017. https://doi.org/10.1016/j.ejogrb.2016.07.497.CrossRefPubMed

129.

Stratton P, Berkley KJ. Chronic pelvic pain and endometriosis: Translational evidence of the relationship and implications. Hum Reprod Update. 2011. https://doi.org/10.1093/humupd/dmq050.CrossRefPubMed

130.

Morotti M, Vincent K, Brawn J, Zondervan KT, Becker CM. Peripheral changes in endometriosis-associated pain. Hum Reprod Update. 2014. https://doi.org/10.1093/humupd/dmu021.CrossRefPubMed

131.

Brawn J, Morotti M, Zondervan KT, Becker CM, Vincent K. Central changes associated with chronic pelvic pain and endometriosis. Hum Reprod Update. 2014. https://doi.org/10.1093/humupd/dmu025.CrossRefPubMed

132.

Barcena de Arellano ML, Arnold J, Lang H, et al. Evidence of neurotrophic events due to peritoneal endometriotic lesions. Cytokine. 2013. https://doi.org/10.1016/j.cyto.2013.03.003.

133.

Krizsan-Agbas D, Pedchenko T, Hasan W, Smith PG. Oestrogen regulates sympathetic neurite outgrowth by modulating brain derived neurotrophic factor synthesis and release by the rodent uterus. Eur J Neurosci. 2003. https://doi.org/10.1111/j.1460-9568.2003.03029.x.CrossRefPubMed

134.

Tokushige N, Markham R, Russell P, Fraser IS. Nerve fibres in peritoneal endometriosis. Hum Reprod. 2006. https://doi.org/10.1093/humrep/del260.CrossRefPubMed

135.

Wang G, Tokushige N, Markham R, Fraser IS. Rich innervation of deep infiltrating endometriosis. Hum Reprod. 2009. https://doi.org/10.1093/humrep/den464.CrossRefPubMed

136.

Riccio L da GC, Santulli P, Marcellin L, Abrão MS, Batteux F, Chapron C. Immunology of endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018. https://doi.org/10.1016/j.bpobgyn.2018.01.010.

137.

Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain. 2011. https://doi.org/10.1016/j.pain.2010.09.030.CrossRefPubMed

138.

As-Sanie S, Harris RE, Napadow V, et al. Changes in regional gray matter volume in women with chronic pelvic pain: A voxel-based morphometry study. Pain. 2012. https://doi.org/10.1016/j.pain.2012.01.032.CrossRefPubMedPubMedCentral

139.

As-Sanie S, Kim J, Schmidt-Wilcke T, et al. Functional Connectivity Is Associated with Altered Brain Chemistry in Women with Endometriosis-Associated Chronic Pelvic Pain. J Pain. 2016. https://doi.org/10.1016/j.jpain.2015.09.008.

140.

Vannuccini S, Lazzeri L, Orlandini C, et al. Mental health, pain symptoms and systemic comorbidities in women with endometriosis: a cross-sectional study. J Psychosom Obstet Gynecol. 2017. https://doi.org/10.1080/0167482X.2017.1386171.CrossRef

141.

McPeak AE, Allaire C, Williams C, Albert A, Lisonkova S, Yong PJ. Pain Catastrophizing and pain health-related quality-of-life in endometriosis. Clin J Pain. 2018;34.

142.

Laganà AS, La Rosa VL, Rapisarda AMC, et al. Anxiety and depression in patients with endometriosis: Impact and management challenges. Int J Womens Health. 2017. https://doi.org/10.2147/IJWH.S119729.CrossRefPubMedPubMedCentral

143.

Álvarez-Salvago F, Lara-Ramos A, Cantarero-Villanueva I, et al. Chronic fatigue, physical impairments and quality of life in women with endometriosis: A case-control study. Int J Environ Res Public Health. 2020. https://doi.org/10.3390/ijerph17103610.CrossRefPubMedPubMedCentral

144.

Jones GT. Psychosocial vulnerability and early life adversity as risk factors for central sensitivity syndromes. Curr Rheumatol Rev. 2016. https://doi.org/10.2174/1573397112666151231113438.

145.

Kvaskoff M, Mu F, Terry KL, et al. Endometriosis: a high-risk population for major chronic diseases? Hum Reprod Update. 2015;21(4):500–16. https://doi.org/10.1093/humupd/dmv013.CrossRefPubMedPubMedCentral

146.

Jess T, Frisch M, Jorgensen KT, Pedersen BV, Nielsen NM. Increased risk of inflammatory bowel disease in women with endometriosis: a nationwide Danish cohort study. Gut. 2012;61(9):1279–83. https://doi.org/10.1136/gutjnl-2011-301095.CrossRefPubMed

147.

Bungum HF, Vestergaard C, Knudsen UB. Endometriosis and type 1 allergies/immediate type hypersensitivity: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2014;179:209–15. https://doi.org/10.1016/j.ejogrb.2014.04.025.CrossRefPubMed

148.

Caserta D, Mallozzi M, Pulcinelli FM, Mossa B, Moscarini M. Endometriosis allergic or autoimmune disease: pathogenetic aspects--a case control study. Clin Exp Obs Gynecol. 2016;43. PMID: 27328490.

149.

Harris HR, Costenbader KH, Mu F, et al. Endometriosis and the risks of systemic lupus erythematosus and rheumatoid arthritis in the Nurses’ health study II. Ann Rheum Dis. 2016;75. https://doi.org/10.1136/annrheumdis-2015-207704.

150.

Greenbaum H, Weil C, Chodick G, Shalev V, Eisenberg VH. Evidence for an association between endometriosis, fibromyalgia, and autoimmune diseases. Am J Reprod Immunol. 2019;81. https://doi.org/10.1111/aji.13095.

151.

Nielsen NM, Jorgensen KT, Pedersen B V, Rostgaard K, Frisch M. The co-occurrence of endometriosis with multiple sclerosis, systemic lupus erythematosus and Sjogren syndrome. Hum Reprod. 2011;26. https://doi.org/10.1093/humrep/der105.

152.

Tariverdian N, Theoharides TC, Siedentopf F, et al. Neuroendocrine-immune disequilibrium and endometriosis: an interdisciplinary approach. Semin Immunopathol. 2007;29. https://doi.org/10.1007/s00281-007-0077-0.

153.

Shigesi N, Kvaskoff M, Kirtley S, et al. The association between endometriosis and autoimmune diseases: A systematic review and meta-analysis. Hum Reprod Update. 2019. https://doi.org/10.1093/humupd/dmz014.CrossRefPubMedPubMedCentral

154.

Tomassetti C, D’Hooghe T. Endometriosis and infertility: Insights into the causal link and management strategies. Best Pract Res Clin Obstet Gynaecol. 2018. https://doi.org/10.1016/j.bpobgyn.2018.06.002.CrossRefPubMed

155.

Tanbo T, Fedorcsak P. Endometriosis-associated infertility: aspects of pathophysiological mechanisms and treatment options. Acta Obstet Gynecol Scand. 2017. https://doi.org/10.1111/aogs.13082.CrossRefPubMed

156.

Dueholm M. Uterine adenomyosis and infertility, review of reproductive outcome after in vitro fertilization and surgery. Acta Obstet Gynecol Scand. 2017;96(6):715–26. https://doi.org/10.1111/aogs.13158.CrossRefPubMed

157.

Campo S, Campo V, Benagiano G. Adenomyosis and infertility. Reprod Biomed Online. 2012;24(1):35–46. https://doi.org/10.1016/j.rbmo.2011.10.003.CrossRefPubMed

158.

Lessey BA, Kim JJ. Endometrial receptivity in the eutopic endometrium of women with endometriosis: it is affected, and let me show you why. Fertil Steril. 2017. https://doi.org/10.1016/j.fertnstert.2017.05.031.CrossRefPubMedPubMedCentral

159.

Miravet-Valenciano J, Ruiz-Alonso M, Gómez E, Garcia-Velasco JA. Endometrial receptivity in eutopic endometrium in patients with endometriosis: it is not affected, and let me show you why. Fertil Steril. 2017. https://doi.org/10.1016/j.fertnstert.2017.06.002.CrossRefPubMed

160.

Barra F, Grandi G, Tantari M, Scala C, Facchinetti F, Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019. https://doi.org/10.1080/14712598.2019.1581761.CrossRefPubMed

161.

Levine D, Kaufman L, Cuenca VG, Badawy SZA. Cell growth effects of leuprolide on cultured endometrioma cells. J Reprod Med. 2007;52(7):581–4 (PMID: 17847754).PubMed

162.

Barra F, Grandi G, Tantari M, Scala C, Facchinetti F, Ferrero S. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019;19(4):343–60. https://doi.org/10.1080/14712598.2019.1581761.CrossRefPubMed

163.

Fedele L, Bianchi S, Bocciolone L, Di Nola G, Franchi D. Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study. Fertil Steril. 1993;59(3):516–21. https://doi.org/10.1016/s0015-0282(16)55792-6.CrossRefPubMed

164.

Bergqvist A, Bergh T, Hogström L, Mattsson S, Nordenskjöld F, Rasmussen C. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril. 1998;69(4):702–8. https://doi.org/10.1016/s0015-0282(98)00019-3.CrossRefPubMed

165.

Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group Fertil Steril. 1990;54(3):419–27. https://doi.org/10.1016/s0015-0282(16)53755-8.CrossRef

166.

Miller JD. Leuprolide acetate for the treatment of endometriosis. Prog Clin Biol Res. 1990;323:337–41.PubMed

167.

Brown J, Pan A, Hart RJ. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane database Syst Rev. 2010. https://doi.org/10.1002/14651858.CD008475.pub2.

168.

Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane database Syst Rev. 2006. https://doi.org/10.1002/14651858.CD004635.pub2.

169.

Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29(3):400–12. https://doi.org/10.1093/humrep/det457.CrossRefPubMed

170.

Tosti C, Biscione A, Morgante G, Bifulco G, Luisi S, Petraglia F. Ac ce pt cr t. Eur J Obstet Gynecol. 2016. https://doi.org/10.1016/j.ejogrb.2016.05.032.CrossRef

171.

Mitwally MFM, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause. 2002;9(4):236–41. https://doi.org/10.1097/00042192-200207000-00004.CrossRefPubMed

172.

Bedaiwy MA, Casper RF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril. 2006;86(1):220–2. https://doi.org/10.1016/j.fertnstert.2005.12.030.CrossRefPubMed

173.

Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist. N Engl J Med. 2017;377(1):28–40. https://doi.org/10.1056/NEJMoa1700089.CrossRefPubMed

174.

Agarwal SK, Singh SS, Archer DF, et al. Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix. J Pain Res. 2021;14:263–71. https://doi.org/10.2147/JPR.S284703.CrossRefPubMedPubMedCentral

175.

Surrey E, Taylor HS, Giudice L, et al. Long-term outcomes of elagolix in women with endometriosis results from two extension studies. Obstet Gynecol. 2018;132(1):147–60. https://doi.org/10.1097/AOG.0000000000002675.CrossRefPubMed

176.

Pokrzywinski RM, Soliman AM, Chen J, et al. Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: analysis of 2 phase III clinical trials. Am J Obstet Gynecol. 2020;222(6):592.e1-592.e10. https://doi.org/10.1016/j.ajog.2019.11.1255.CrossRef

177.

Surrey ES, Soliman AM, Agarwal SK, Snabes MC, Diamond MP. Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis. Fertil Steril. 2019;112(2):298-304.e3. https://doi.org/10.1016/j.fertnstert.2019.02.031.CrossRefPubMed

178.

Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683–91. https://doi.org/10.1210/jc.2016-3845.CrossRefPubMed

179.

Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009;94(2):545–51. https://doi.org/10.1210/jc.2008-1695.CrossRefPubMed

180.

Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2020:1–8. https://doi.org/10.1016/j.fertnstert.2020.07.055.

181.

Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertil Steril. 2020;114(1):44–55. https://doi.org/10.1016/j.fertnstert.2020.02.114.CrossRefPubMed

182.

Dunselman GAJ, Vermeulen N, Becker C, et al. ESHRE guideline: Management of women with endometriosis. Hum Reprod. 2014. https://doi.org/10.1093/humrep/det457.CrossRefPubMed

183.

Vercellini P, Buggio L, Berlanda N, Barbara G, Somigliana E, Bosari S. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016. https://doi.org/10.1016/j.fertnstert.2016.10.022.CrossRefPubMed

184.

Quaas AM, Weedin EA, Hansen KR. On-label and off-label drug use in the treatment of endometriosis. Fertil Steril. 2015;103(3):612–25. https://doi.org/10.1016/j.fertnstert.2015.01.006.CrossRefPubMed

185.

Vercellini P, Buggio L, Frattaruolo MP, Borghi A, Dridi D, Somigliana E. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018. https://doi.org/10.1016/j.bpobgyn.2018.01.015.CrossRefPubMed

186.

Lee JH, Song JY, Yi KW, et al. Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data. Reprod Sci. 2018;25(10):1515–22. https://doi.org/10.1177/1933719118779733.CrossRefPubMed

187.

Techatraisak K, Hestiantoro A, Ruey S, et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under real-life clinical practice. BMC Womens Health. 2019;19(1):68. https://doi.org/10.1186/s12905-019-0758-6.CrossRefPubMedPubMedCentral

188.

García Uranga-Romano J, Hernández-Valencia M, Zárate A, Basavilvazo-Rodríguez MA. Dienogest usefulness in pelvic pain due to endometriosis. A meta-analysis of its effectiveness. Rev Med Inst Mex Seguro Soc. 2017;55(4):452–55. PMID: 28591499.

189.

Momoeda M, Harada T, Terakawa N, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009;35(6):1069–76. https://doi.org/10.1111/j.1447-0756.2009.01076.x.CrossRefPubMed

190.

Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2020;36(1):81–3. https://doi.org/10.1080/09513590.2019.1640199.CrossRef

191.

Vignali M, Belloni GM, Pietropaolo G, et al. Effect of Dienogest therapy on the size of the endometrioma. Gynecol Endocrinol. 2020. https://doi.org/10.1080/09513590.2020.1725965.CrossRefPubMed

192.

Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020. https://doi.org/10.1080/09513590.2019.1640674.CrossRefPubMed

193.

Del Forno S, Mabrouk M, Arena A, et al. Dienogest or Norethindrone acetate for the treatment of ovarian endometriomas: Can we avoid surgery? Eur J Obstet Gynecol Reprod Biol. 2019. https://doi.org/10.1016/j.ejogrb.2019.04.010.CrossRefPubMed

194.

Papíková Z, Hudeček R, Ventruba P, Szypulová M. Efficacy of dienogest treatment of clinical symptoms of rectovaginal endometriosis. Ces Gynekol. 2019;84(5):331–6.

195.

Leone Roberti Maggiore U, Ferrero S, Candiani M, Somigliana E, Viganò P, Vercellini P. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol. 2017;71(5):790–807. https://doi.org/10.1016/j.eururo.2016.12.015.

196.

Angioni S, Nappi L, Pontis A, et al. Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2015;31(5):406–8. https://doi.org/10.3109/09513590.2015.1006617.

197.

Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017;211:108–11. https://doi.org/10.1016/j.ejogrb.2017.02.015.CrossRefPubMed

198.

Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, Yela DA. Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstet Gynecol Reprod Biol. 2017. https://doi.org/10.1016/j.ejogrb.2017.02.015.CrossRefPubMed

199.

Caruso S, Iraci M, Cianci S, Vitale SG, Fava V, Cianci A. Effects of long-term treatment with Dienogest on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain. J Pain Res. 2019;12:2371–8. https://doi.org/10.2147/JPR.S207599.CrossRefPubMedPubMedCentral

200.

Techatraisak K, Hestiantoro A, Ruey S, et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): Interim results from a prospective cohort study under real-life clinical practice. BMC Womens Health. 2019. https://doi.org/10.1186/s12905-019-0758-6.CrossRefPubMedPubMedCentral

201.

Yu Q, Zhang S, Li H, et al. Dienogest for treatment of endometriosis in women: A 28-week, open-label, extension study. J Women’s Heal. 2019. https://doi.org/10.1089/jwh.2018.7084.CrossRef

202.

Römer T. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice. Arch Gynecol Obstet. 2018. https://doi.org/10.1007/s00404-018-4864-8.CrossRefPubMed

203.

Zakhari A, Edwards D, Ryu M, Matelski JJ, Bougie O, Murji A. Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2020;27(7):1503–10. https://doi.org/10.1016/j.jmig.2020.05.007.CrossRefPubMed

204.

Cho BS, Roh JW, Park J, et al. Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study. Reprod Sci. 2020. https://doi.org/10.1007/s43032-019-00094-5.CrossRefPubMed

205.

Lee DY, Lee JY, Seo JW, Yoon BK, Choi DS. Gonadotropin-releasing hormone agonist with add–back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis. Arch Gynecol Obstet. 2016. https://doi.org/10.1007/s00404-016-4184-9.CrossRefPubMed

206.

Seo JW, Lee DY, Kim SE, Yoon BK, Choi DS. Comparison of long-term use of combined oral contraceptive after gonadotropin-releasing hormone agonist plus add-back therapy versus dienogest to prevent recurrence of ovarian endometrioma after surgery. Eur J Obstet Gynecol Reprod Biol. 2019. https://doi.org/10.1016/j.ejogrb.2019.02.032.CrossRefPubMed

207.

Koshiba A, Mori T, Okimura H, et al. Dienogest therapy during the early stages of recurrence of endometrioma might be an alternative therapeutic option to avoid repeat surgeries. J Obstet Gynaecol Res. 2018. https://doi.org/10.1111/jog.13725.CrossRefPubMed

208.

Vercellini P, Bracco B, Mosconi P, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: A before and after study. Fertil Steril. 2016. https://doi.org/10.1016/j.fertnstert.2015.11.016.CrossRefPubMed

209.

Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005. https://doi.org/10.1016/j.fertnstert.2005.03.083.CrossRefPubMed

210.

Ferrero S, Camerini G, Ragni N, Venturini PL, Biscaldi E, Remorgida V. Norethisterone acetate in the treatment of colorectal endometriosis: A pilot study. Hum Reprod. 2010. https://doi.org/10.1093/humrep/dep361.CrossRefPubMed

211.

Morotti M, Venturini PL, Biscaldi E, et al. Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. Eur J Obstet Gynecol Reprod Biol. 2017. https://doi.org/10.1016/j.ejogrb.2017.03.033.CrossRefPubMed

212.

Scala C, Leone Roberti Maggiore U, Barra F, Venturini PL, Ferrero S. Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique ®) in the treatment of endometriosis symptoms: A prospective open-label comparative study. Eur J Obstet Gynecol Reprod Biol. 2018. https://doi.org/10.1016/j.ejogrb.2018.01.022.

213.

Morotti M, Sozzi F, Remorgida V, Venturini PL, Ferrero S. Dienogest in women with persistent endometriosis-related pelvic pain during norethisterone acetate treatment. Eur J Obstet Gynecol Reprod Biol. 2014. https://doi.org/10.1016/j.ejogrb.2014.10.036.CrossRefPubMed

214.

Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD002122.pub2.

215.

Telimaa S, Puolakka J, Rönnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 1987;1(1):13–23. https://doi.org/10.3109/09513598709082692.CrossRef

216.

Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21(1):248–56. https://doi.org/10.1093/humrep/dei290.CrossRefPubMed

217.

Schlaff WD, Carson SA, Luciano A, Ross D, Bergqvist A. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril. 2006;85(2):314–25. https://doi.org/10.1016/j.fertnstert.2005.07.1315.CrossRefPubMed

218.

Committee Opinion No. 602: Depot medroxyprogesterone acetate and bone effects. Obstet Gynecol. 2014;123(6):1398–402. https://doi.org/10.1097/01.AOG.0000450758.95422.c8.CrossRef

219.

Olive DL. Medical therapy of endometriosis. Semin Reprod Med. 2003;21(2):209–22. https://doi.org/10.1055/s-2003-41327.CrossRefPubMed

220.

Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane database Syst Rev. 2007. https://doi.org/10.1002/14651858.CD000068.pub2.

221.

Cobellis L, Razzi S, Fava A, Severi FM, Igarashi M, Petraglia F. A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis. Fertil Steril. 2004;82(1):239–40. https://doi.org/10.1016/j.fertnstert.2003.11.058.CrossRefPubMed

222.

Igarashi M, Iizuka M, Abe Y, Ibuki Y. Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis. Hum Reprod. 1998;13(7):1952–6. https://doi.org/10.1093/humrep/13.7.1952.CrossRefPubMed

223.

Razzi S, Luisi S, Calonaci F, Altomare A, Bocchi C, Petraglia F. Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril. 2007;88(4):789–94. https://doi.org/10.1016/j.fertnstert.2006.12.077.CrossRefPubMed

224.

Godin R, Marcoux V. Vaginally Administered Danazol: An Overlooked Option in the Treatment of Rectovaginal Endometriosis? J Obstet Gynaecol Canada JOGC = J d’obstetrique Gynecol du Canada JOGC. 2015;37(12):1098–103. https://doi.org/10.1016/s1701-2163(16)30075-5

225.

Okamura Y, Suzuki J, Honda R, Ohba T, Katabuchi H, Okamura H. Clinical outcome of vaginal danazol suppository use in women with pelvic endometriosis. Fertil Steril. 2008. https://doi.org/10.1016/j.fertnstert.2008.07.072.CrossRefPubMed

226.

Bhattacharya SM, Tolasaria A, Khan B. Vaginal danazol for the treatment of endometriosis-related pelvic pain. Int J Gynecol Obstet. 2011. https://doi.org/10.1016/j.ijgo.2011.06.021.CrossRef

227.

Razzi S, Luisi S, Ferretti C, et al. Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2007;135(2):188–90. https://doi.org/10.1016/j.ejogrb.2006.08.002.CrossRefPubMed

228.

Morotti M, Remorgida V, Venturini PL, Ferrero S. Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. Eur J Obstet Gynecol Reprod Biol. 2014;183:178–82. https://doi.org/10.1016/j.ejogrb.2014.10.029.CrossRefPubMed

229.

Leone Roberti Maggiore U, Remorgida V, Scala C, Tafi E, Venturini PL, Ferrero S. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand. 2014;93(3):239–47. https://doi.org/10.1111/aogs.12326.

230.

Viganò P, Somigliana E, Vercellini P. Levonorgestrel-releasing intrauterine system for the treatment of endometriosis: Biological and clinical evidence. Women’s Heal. 2007. https://doi.org/10.2217/17455057.3.2.207.CrossRef

231.

Vercellini P, Frontino G, De Giorgi O, Aimi G, Zaina B, Crosignani PG. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril. 2003;80(2):305–9. https://doi.org/10.1016/s0015-0282(03)00608-3.CrossRefPubMed

232.

Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95(2):492–6. https://doi.org/10.1016/j.fertnstert.2010.08.042.CrossRefPubMed

233.

Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Indhavivadhana S, Leerasiri P. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119(3):519–26. https://doi.org/10.1097/AOG.0b013e31824264c3.CrossRefPubMed

234.

Yucel N, Baskent E, Karamustafaoglu Balci B, Goynumer G. The levonorgestrel-releasing intrauterine system is associated with a reduction in dysmenorrhoea and dyspareunia, a decrease in CA 125 levels, and an increase in quality of life in women with suspected endometriosis. Aust New Zeal J Obstet Gynaecol. 2018. https://doi.org/10.1111/ajo.12773.CrossRef

235.

Lee KH, Jung YW, Song SY, et al. Comparison of the efficacy of diegnogest and levonorgestrel-releasing intrauterine system after laparoscopic surgery for endometriosis. J Obstet Gynaecol Res. 2018. https://doi.org/10.1111/jog.13703.CrossRefPubMed

236.

Chen Y-J, Hsu T-F, Huang B-S, Tsai H-W, Chang Y-H, Wang P-H. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol. 2017;216(6):582.e1-582.e9. https://doi.org/10.1016/j.ajog.2017.02.008.CrossRef

237.

Wattanayingcharoenchai R, Rattanasiri S, Charakorn C, Attia J, Thakkinstian A. Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis. BJOG An Int J Obstet Gynaecol. 2021. https://doi.org/10.1111/1471-0528.16366.CrossRef

238.

Song J, Wang Y, Yu L. Clinical comparison of mifepristone and gestrinone for laparoscopic endometriosis. Pak J Pharm Sci. 2018;31(5):2197–201.PubMed

239.

Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis–a pilot study. Contraception. 2009;79(1):29–34. https://doi.org/10.1016/j.contraception.2008.07.017.CrossRefPubMed

240.

Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plan Reprod Heal care. 2005;31(1):67–70. https://doi.org/10.1783/0000000052972799.CrossRef

241.

Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial. Fertil Steril. 2018. https://doi.org/10.1016/j.fertnstert.2018.07.003.CrossRefPubMed

242.

Alio L, Angioni S, Arena S, et al. When more is not better: 10 ‘don’ts’ in endometriosis management. An ETIC* position statement. Hum Reprod Open. 2019. https://doi.org/10.1093/hropen/hoz009.

243.

Meresman GF, Augé L, Barañao RI, Lombardi E, Tesone M, Sueldo C. Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil Steril. 2002;77(6):1141–7. https://doi.org/10.1016/s0015-0282(02)03099-6.CrossRefPubMed

244.

Harada T, Momoeda M, Taketani Y, Hoshiai H, Terakawa N. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008;90(5):1583–8. https://doi.org/10.1016/j.fertnstert.2007.08.051.CrossRefPubMed

245.

Harada T, Kosaka S, Elliesen J, Yasuda M, Ito M, Momoeda M. Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil Steril. 2017;108(5):798–805. https://doi.org/10.1016/j.fertnstert.2017.07.1165.CrossRefPubMed

246.

Brown J, Crawford TJ, Datta S, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev. 2018. https://doi.org/10.1002/14651858.CD001019.pub3.

247.

Becker CM, Gattrell WT, Gude K, Singh SS. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil Steril. 2017. https://doi.org/10.1016/j.fertnstert.2017.05.004.CrossRefPubMedPubMedCentral

248.

Jenkins TR, Liu CY, White J. Does Response to Hormonal Therapy Predict Presence or Absence of Endometriosis? J Minim Invasive Gynecol. 2008. https://doi.org/10.1016/j.jmig.2007.09.002.CrossRefPubMed

249.

Bernuit D, Ebert AD, Halis G, et al. Female perspectives on endometriosis: Findings from the uterine bleeding and pain women’s research study. J Endometr. 2011. https://doi.org/10.5301/JE.2011.8525.CrossRef

250.

Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertil Steril. 2017;107(3):533–6. https://doi.org/10.1016/j.fertnstert.2017.01.003.CrossRefPubMed

251.

Vercellini P, Eskenazi B, Consonni D, et al. Oral contraceptives and risk of endometriosis: A systematic review and meta-analysis. Hum Reprod Update. 2011. https://doi.org/10.1093/humupd/dmq042.CrossRefPubMed

252.

Seracchioli R, Mabrouk M, Manuzzi L, et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Hum Reprod. 2009;24(11):2729–35. https://doi.org/10.1093/humrep/dep259.CrossRefPubMed

253.

Seracchioli R, Mabrouk M, Frascà C, Manuzzi L, Savelli L, Venturoli S. Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial. Fertil Steril. 2010;94(2):464–71. https://doi.org/10.1016/j.fertnstert.2009.03.083.CrossRefPubMed

254.

Takamura M, Koga K, Osuga Y, et al. Post-operative oral contraceptive use reduces the risk of ovarian endometrioma recurrence after laparoscopic excision. Hum Reprod. 2009;24(12):3042–8. https://doi.org/10.1093/humrep/dep297.CrossRefPubMed

255.

Wu L, Wu Q, Liu L. Oral contraceptive pills for endometriosis after conservative surgery: a systematic review and meta-analysis. Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol. 2013;29(10):883–90. https://doi.org/10.3109/09513590.2013.819085.CrossRef

256.

Muzii L, Di Tucci C, Achilli C, et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian endometriomas: A systematic review and metaanalysis. Am J Obstet Gynecol. 2016;214(2):203–11. https://doi.org/10.1016/j.ajog.2015.08.074.CrossRefPubMed

257.

Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: a systematic review. Arch Gynecol Obstet. 2015;292(1):37–43. https://doi.org/10.1007/s00404-015-3641-1.CrossRefPubMed

258.

Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77(1):52–61. https://doi.org/10.1016/s0015-0282(01)02951-x.CrossRefPubMed

259.

Zupi E, Marconi D, Sbracia M, et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril. 2004;82(5):1303–8. https://doi.org/10.1016/j.fertnstert.2004.03.062.CrossRefPubMed

260.

Chwalisz K, Perez MC, DeManno D, Winkel C, Schubert G, Elger W. Selective Progesterone Receptor Modulator Development and Use in the Treatment of Leiomyomata and Endometriosis. Endocr Rev. 2005;26(3):423–38. https://doi.org/10.1210/er.2005-0001.CrossRefPubMed

261.

Goenka L, George M, Sen M. A peek into the drug development scenario of endometriosis – A systematic review. Biomed Pharmacother. 2017;90:575–85. https://doi.org/10.1016/j.biopha.2017.03.092.CrossRefPubMed

262.

Rocha ALL, Reis FM, Petraglia F. New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs. 2012. https://doi.org/10.1517/13543784.2012.683783.CrossRefPubMed

263.

Islam MS, Afrin S, Jones SI SJ. Selective progesterone receptor modulators-mechanisms and therapeutic utility. Endocr Rev. 2020;41(5):bnaa012. PMID: 32365199.

264.

Bruner-Tran KL, Zhang Z, Eisenberg E, Winneker RC, Osteen KG. Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. J Clin Endocrinol Metab. 2006;91(4):1554–60. https://doi.org/10.1210/jc.2005-2024.CrossRefPubMed

265.

Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen SS. Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis. Fertil Steril. 1991;56(3):402–7. https://doi.org/10.1016/s0015-0282(16)54531-2.CrossRefPubMed

266.

Kettel LM, Murphy AA, Morales AJ, Ulmann A, Baulieu EE, Yen SS. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril. 1996;65(1):23–8. https://doi.org/10.1016/s0015-0282(16)58022-4.CrossRefPubMed

267.

Carbonell JL, Riverón AM, Leonard Y, González J, Heredia B SC. Mifepristone 2.5, 5, 10 mg versus placebo in the treatment of endometriosis. J Reprod Heal Med. 2016;217–25.

268.

ChwaliszC. Mattia-Goldberg K, Lee M, Elger W, Edmonds A. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil. Fertil Steril. 2004;82:S83–84. https://doi.org/10.1016/j.fertnstert.2004.07.212.

269.

Singh SS, Evans D, McDonald S, Senterman M, Strickland S. Ulipristal Acetate Prior to Surgery for Endometriosis. Reprod Sci. 2020. https://doi.org/10.1007/s43032-020-00146-1.CrossRefPubMed

270.

Yao Z, Shen X, Capodanno I, et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Investig Surg Off J Acad Surg Res. 2005;18(4):177–83. https://doi.org/10.1080/08941930591004412.CrossRef

271.

Altintas D, Kokcu A, Kandemir B, Tosun M, Cetinkaya MB. Comparison of the effects of raloxifene and anastrozole on experimental endometriosis. Eur J Obstet Gynecol Reprod Biol. 2010;150(1):84–7. https://doi.org/10.1016/j.ejogrb.2010.02.004.CrossRefPubMed

272.

Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol. 2008;111(1):88–96. https://doi.org/10.1097/01.AOG.0000297307.35024.b5.CrossRefPubMedPubMedCentral

273.

Kulak JJ, Fischer C, Komm B, Taylor HS. Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model. Endocrinology. 2011;152(8):3226–32. https://doi.org/10.1210/en.2010-1010.CrossRefPubMedPubMedCentral

274.

Harada T, Ohta I, Endo Y, Sunada H, Noma H, Taniguchi F. SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial. Yonago Acta Med. 2017;60(4):227–33. https://doi.org/10.24563/yam.2017.12.003.CrossRefPubMed

275.

Velasco I, Rueda J, Acién P. Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis. Mol Hum Reprod. 2006;12(6):377–81. https://doi.org/10.1093/molehr/gal041.CrossRefPubMed

276.

Rafique S, Decherney AH. Medical Management of Endometriosis. Clin Obstet Gynecol. 2017. https://doi.org/10.1097/GRF.0000000000000292.CrossRefPubMedPubMedCentral

277.

Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89. https://doi.org/10.1186/1477-7827-9-89.CrossRefPubMedPubMedCentral

278.

Sibiude J, Santulli P, Marcellin L, Borghese B, Dousset B, Chapron C. Association of history of surgery for endometriosis with severity of deeply infiltrating endometriosis. Obstet Gynecol. 2014. https://doi.org/10.1097/AOG.0000000000000464.CrossRefPubMed

279.

Goodman LR, Goldberg JM, Flyckt RL, Gupta M, Harwalker J, Falcone T. Effect of surgery on ovarian reserve in women with endometriomas, endometriosis and controls. Am J Obstet Gynecol. 2016. https://doi.org/10.1016/j.ajog.2016.05.029

280.

Leyland N, Casper R, Laberge P, Singh SS, SOGC. Endometriosis: diagnosis and management. J Obstet Gynaecol Can. 2010;32(7 Suppl 2):S1–32. http://www.ncbi.nlm.nih.gov/pubmed/21545757.

281.

Practice bulletin no. 114: Management of endometriosis. Obstet Gynecol. 2010. https://doi.org/10.1097/AOG.0b013e3181e8b073.CrossRef

282.

Kuznetsov L, Dworzynski K, Davies M, Overton C. Diagnosis and management of endometriosis: summary of NICE guidance. BMJ. September 2017:j3935. https://doi.org/10.1136/bmj.j3935.

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hormonal treatments for endometriosis: The endocrine background

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Diabetes complications and extracellular vesicle therapy

Pasireotide—a novel somatostatin receptor ligand after 20 years of use

The emerging role of transcription factor FOXP3 in thyroid cancer

The effects of cannabis and cannabinoids on the endocrine system